<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: December ", fill: "#b768a2"},
{source: "6: December ", target: "6: accumulated deficit", fill: "#b768a2"},
{source: "6: December ", target: "8: future losses will depend", fill: "#826644"},
{source: "8: future losses will depend", target: "8: contract revenue future product", fill: "#826644"},
{source: "8: contract revenue future product", target: "8: sales at profitable margins", fill: "#826644"},
{source: "8: future losses will depend", target: "9: date most", fill: "#fff8dc"},
{source: "9: date most", target: "9: been derived from collaborations", fill: "#fff8dc"},
{source: "9: been derived from collaborations", target: "9: significant", fill: "#fff8dc"},
{source: "9: significant", target: "9: same sources", fill: "#fff8dc"},
{source: "9: date most", target: "10: revenue from collaborations", fill: "#ca1f7b"},
{source: "10: revenue from collaborations", target: "10: collaborations", fill: "#ca1f7b"},
{source: "10: collaborations", target: "10: revenue will depend upon", fill: "#ca1f7b"},
{source: "10: revenue will depend upon", target: "10: new collaborations", fill: "#ca1f7b"},
{source: "10: new collaborations", target: "10: meet research", fill: "#ca1f7b"},
{source: "10: meet research", target: "10: development", fill: "#ca1f7b"},
{source: "10: development", target: "10: commercialization objectives under new", fill: "#ca1f7b"},
{source: "10: commercialization objectives under new", target: "10: agreements", fill: "#ca1f7b"},
{source: "10: revenue from collaborations", target: "13: generate revenue", fill: "#2f847c"},
{source: "13: generate revenue", target: "13: existing collaborations andor", fill: "#2f847c"},
{source: "13: existing collaborations andor", target: "13: attract new ones", fill: "#2f847c"},
{source: "13: attract new ones", target: "13: milestones under them but", fill: "#2f847c"},
{source: "13: milestones under them but", target: "13: technologies", fill: "#2f847c"},
{source: "13: technologies", target: "13: partners choose", fill: "#2f847c"},
{source: "13: partners choose", target: "13: commercialize", fill: "#2f847c"},
{source: "13: commercialize", target: "13: commercially successful", fill: "#2f847c"},
{source: "13: commercially successful", target: "13: derive revenue", fill: "#2f847c"},
{source: "13: derive revenue", target: "13: through sales", fill: "#2f847c"},
{source: "13: generate revenue", target: "21: addition four", fill: "#cd5c5c"},
{source: "21: addition four", target: "21: collaborative partners", fill: "#cd5c5c"},
{source: "21: collaborative partners", target: "21: formerly known as", fill: "#cd5c5c"},
{source: "21: addition four", target: "36: future strategic alliance", fill: "#76ff7a"},
{source: "36: future strategic alliance", target: "36: collaboration opportunities could", fill: "#76ff7a"},
{source: "36: collaboration opportunities could", target: "36: objectives", fill: "#76ff7a"},
{source: "36: objectives", target: "36: collaboration agreements", fill: "#76ff7a"},
{source: "36: collaboration agreements", target: "36: enter into additional strategic", fill: "#76ff7a"},
{source: "36: enter into additional strategic", target: "36: collaborations", fill: "#76ff7a"},
{source: "36: collaborations", target: "36: conflict with", fill: "#76ff7a"},
{source: "36: conflict with", target: "36: strategic partners", fill: "#76ff7a"},
{source: "36: strategic partners", target: "36: collaborators", fill: "#76ff7a"},
{source: "36: collaborators", target: "36: disagree with", fill: "#76ff7a"},
{source: "36: disagree with", target: "36: collaborators as", fill: "#76ff7a"},
{source: "36: collaborators as", target: "36: intellectual property", fill: "#76ff7a"},
{source: "36: intellectual property", target: "36: research programs", fill: "#76ff7a"},
{source: "36: research programs", target: "36: commercialization activities", fill: "#76ff7a"},
{source: "36: commercialization activities", target: "36: manage multiple simultaneous strategic alliances", fill: "#76ff7a"},
{source: "36: manage multiple simultaneous strategic alliances", target: "36: collaborators become competitors", fill: "#76ff7a"},
{source: "36: collaborators become competitors", target: "36: competitors", fill: "#76ff7a"},
{source: "36: competitors", target: "36: enter into agreements with", fill: "#76ff7a"},
{source: "36: enter into agreements with", target: "36: collaborators become less willing", fill: "#76ff7a"},
{source: "36: collaborators become less willing", target: "36: resources on research", fill: "#76ff7a"},
{source: "36: resources on research", target: "36: development due", fill: "#76ff7a"},
{source: "36: development due", target: "36: general market conditions", fill: "#76ff7a"},
{source: "36: general market conditions", target: "36: circumstances beyond", fill: "#76ff7a"},
{source: "36: circumstances beyond", target: "36: Consolidation ", fill: "#76ff7a"},
{source: "36: Consolidation ", target: "36: negotiate additional agreements", fill: "#76ff7a"},
{source: "36: future strategic alliance", target: "START_HERE", fill: "#76ff7a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/L3Harris_Technologies">L3Harris Technologies</a></td>
      <td>L3Harris Technologies (L3Harris) is an American technology company, defense contractor, and information technology services provider that produces C6ISR systems and products, wireless equipment, tactical radios, avionics and electronic systems, night vision equipment, and both terrestrial and spaceborne antennas for use in the government, defense, and commercial sectors. They specialize in surveillance solutions, microwave weaponry, and electronic warfare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DIVERSA CORP      ITEM 1A RISK FACTORS          Except for the historical information <font color="blue">contained herein</font>, this Form 10-K     contains forward-looking statements that <font color="blue">involve risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our actual results <font color="blue">may differ materially from</font> those discussed here</td>
    </tr>
    <tr>
      <td><font color="blue">Factors     </font>that could cause or contribute to <font color="blue">differences</font> in our actual results include     those discussed in the following section, as well as those discussed in Part     II, Item 7 entitled “Management’s Discussion and Analysis of Financial     Condition and Results of Operations” and elsewhere <font color="blue">throughout</font> this Form     10-K You should consider <font color="blue">carefully</font> the following risk factors, together     with all of the other information included in this Form 10-K Each of these     risk factors could <font color="blue">adversely</font> affect our business, operating results, and     financial condition, as well as <font color="blue">adversely</font> affect the value of an <font color="blue">investment</font>     in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have a history of net losses, we expect to continue to <font color="blue">incur net losses</font>,     and we may not achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred net losses since</font> our inception, including a net loss of     <font color="blue">approximately</font>  dlra90 million for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font> dlra290     million</td>
    </tr>
    <tr>
      <td>We  expect to incur additional losses in 2006 and 2007 as we     continue to develop <font color="blue">in<font color="blue">dependent</font> products</font> and as a result of our continued     <font color="blue">investment</font> in our sales and <font color="blue">marketing infrastructure</font> to support anticipated     growth in <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>The extent of our <font color="blue">future losses will depend</font>, in     part, on the rate of growth, if any, in our contract revenue, future product     <font color="blue">sales at profitable margins</font>, and on the level of our expenses</td>
    </tr>
    <tr>
      <td>To date, most     of our revenue has <font color="blue">been <font color="blue">derived from</font> <font color="blue">collaborations</font></font> and grants, and we     expect that a <font color="blue">significant</font> portion of our revenue for 2006 will result from     the <font color="blue">same sources</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">revenue from <font color="blue">collaborations</font></font> is uncertain because our ability to     generate  <font color="blue">revenue will depend upon</font> our ability to maintain our current     <font color="blue">collaborations</font>,  enter  into  new <font color="blue">collaborations</font> and to <font color="blue">meet research</font>,     <font color="blue">development</font>,  and  <font color="blue"><font color="blue">commercialization</font> <font color="blue">objectives</font> under new</font> and existing     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>We anticipate that our sales and <font color="blue">marketing expenses will remain</font>     <font color="blue">at comparable levels</font>, or increase, in <font color="blue">future periods as</font> we <font color="blue">introduce new</font>     products  and  invest  in  the  <font color="blue"><font color="blue">necessary</font> infrastructure</font> to support an     anticipated <font color="blue">increased level</font> of <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>We will need to generate     <font color="blue">significant</font> additional revenue to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In order for us to     <font color="blue">generate revenue</font>, we must not only retain our existing <font color="blue">collaborations</font> and/or     <font color="blue">attract new ones</font> and achieve milestones under them, but we must also develop     products or <font color="blue">technologies</font> that we or our <font color="blue">partners choose</font> to <font color="blue">commercialize</font> and     that  are <font color="blue"><font color="blue">commercially</font> successful</font> and from which we can <font color="blue">derive revenue</font>     <font color="blue">through sales</font> or royalties</td>
    </tr>
    <tr>
      <td>Even if we do achieve <font color="blue">profitability</font>, we may not     be able to sustain or increase <font color="blue">profitability</font> on a quarterly or <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  are  an  <font color="blue"><font color="blue">early stage</font> company</font> developing and <font color="blue">deploying new</font>     <font color="blue">technologies</font>,  we may not be able to <font color="blue">commercialize</font> our <font color="blue">technologies</font> or     products, <font color="blue">which could</font> cause us to be unprofitable or <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>You  must  evaluate  our  business  in  light of the <font color="blue">uncertainties</font> and     <font color="blue">complexities affecting</font> an <font color="blue"><font color="blue">early stage</font> <font color="blue">bio<font color="blue">technology</font></font> company</font></td>
    </tr>
    <tr>
      <td>Our existing     <font color="blue">proprietary</font> <font color="blue">technologies</font> are new and in the <font color="blue">early stage</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We     may not be successful in the commercial <font color="blue">development</font> of these or any further     <font color="blue">technologies</font>  or  products</td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font>products  require <font color="blue">significant</font>     <font color="blue">development</font> and <font color="blue">investment</font>, including testing, to <font color="blue">demonstrate</font> their cost-     <font color="blue">effectiveness prior</font> to <font color="blue"><font color="blue">regulatory</font> approval</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>To date,     we have <font color="blue">commercialize</font>d only eight of our own products, Ultra-Thin^™ enzyme,     Pyrolase^™  160  enzyme,  Pyrolase^™  200  enzyme, Cottonase^™ enzyme,     Luminase^™ PB-100 enzyme, Bayovac^® SRS, and blue and green <font color="blue">fluorescent</font>     proteins</td>
    </tr>
    <tr>
      <td>In addition, four of our <font color="blue"><font color="blue">collaborative</font> partners</font>, Invitrogen     Corporation, Danisco Animal Nutrition, Givaudan Flavors Corporation, and     Syngenta  Animal  Nutrition  (<font color="blue">formerly known as</font> Zymetrics, Inc</td>
    </tr>
    <tr>
      <td>), have     <font color="blue"><font color="blue">incorporate</font>d</font>  our <font color="blue">technologies</font> or <font color="blue"><font color="blue">inventions</font> into</font> their own commercial     <font color="blue">products from which</font> we have generated and/or can <font color="blue">generate royalties</font></td>
    </tr>
    <tr>
      <td>Our     products and <font color="blue">technologies</font> have <font color="blue">generated only</font> modest revenues to date</td>
    </tr>
    <tr>
      <td>Because of these <font color="blue">uncertainties</font>, our <font color="blue">discovery</font> process may not result in the     <font color="blue">identification</font> of <font color="blue">product candidates</font> that we or our <font color="blue"><font color="blue">collaborative</font> partners</font>     will <font color="blue">successfully</font> <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>If we are not able to use our <font color="blue">technologies</font>     to <font color="blue">discover new materials</font> or products with <font color="blue">significant</font> commercial potential,     we will not be able to achieve our <font color="blue">objectives</font> or build a sustainable or     profitable business</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       We  are  <font color="blue">dependent</font>  on  our <font color="blue"><font color="blue">collaborative</font> partners</font>, and our failure to     <font color="blue"><font color="blue">successfully</font> manage</font> our existing and <font color="blue">future collaboration <font color="blue">relationships</font></font>     <font color="blue"><font color="blue">could prevent</font> us from</font> developing and <font color="blue">commercializing</font> many of our products     and achieving or sustaining <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We  currently  have license <font color="blue"><font color="blue">agreement</font>s</font>, <font color="blue">strategic alliance</font> <font color="blue"><font color="blue">agreement</font>s</font>,     collaboration <font color="blue"><font color="blue">agreement</font>s</font>, supply <font color="blue"><font color="blue">agreement</font>s</font>, and/or distribution <font color="blue"><font color="blue">agreement</font>s</font>     with BASF, Bayer Animal Health, Cargill Health and Food Technologies, DSM     Pharma Chemicals, DuPont Bio-Based Materials, Givaudan Flavors Corporation,     Medarex, Merck, Valley Research, inc, and Xoma</td>
    </tr>
    <tr>
      <td>We have also formed a broad     strategic  <font color="blue">relationship with</font> Syngenta AG, a world-leading <font color="blue">agribusiness</font>     company</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, <font color="blue">approximately</font> 45prca of our     revenue was <font color="blue">from <font color="blue">affiliates</font></font> of Syngenta AG, and a major portion of our     <font color="blue">future committed funding</font> is also to be received <font color="blue">from <font color="blue">affiliates</font></font> of Syngenta     AG We expect that a <font color="blue">significant</font> portion of any <font color="blue">future revenue will</font> be     <font color="blue">derived from</font> our collaboration <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Since we do not currently possess     the <font color="blue">resources <font color="blue">necessary</font></font> to in<font color="blue">dependent</font>ly develop and <font color="blue">commercialize</font> all of     the <font color="blue">potential products</font> that may result from our <font color="blue">technologies</font>, we expect to     continue to <font color="blue">enter into</font>, and in the near-term derive additional revenue from,     <font color="blue">strategic alliance</font> and collaboration <font color="blue"><font color="blue">agreement</font>s</font> to develop and <font color="blue">commercialize</font>     products</td>
    </tr>
    <tr>
      <td>We will have limited or <font color="blue">no control over</font> the resources that any     <font color="blue">strategic partner</font> or <font color="blue">collaborator may devote</font> to our <font color="blue">partnered products</font></td>
    </tr>
    <tr>
      <td>Any     of our present or future <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font> may fail to     perform  their  <font color="blue">obligations</font>  as  expected</td>
    </tr>
    <tr>
      <td>These <font color="blue">strategic partner</font>s or     <font color="blue">collaborators</font> may breach or terminate their <font color="blue"><font color="blue">agreement</font>s</font> with us or otherwise     fail to conduct their <font color="blue"><font color="blue">collaborative</font> activities <font color="blue">successfully</font></font> and in a timely     manner</td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font> may not develop     products arising out of our <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font> or <font color="blue">devote sufficient</font>     resources to the <font color="blue">development</font>, <font color="blue">manufacture</font>, marketing, or sale of these     products</td>
    </tr>
    <tr>
      <td>If any of these events occur, or we fail to <font color="blue">enter into</font> or maintain     strategic  alliance or collaboration <font color="blue"><font color="blue">agreement</font>s</font>, we may not be able to     <font color="blue">commercialize</font>  our products, grow our business, or <font color="blue">generate sufficient</font>     revenue to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our present or future <font color="blue">strategic alliance</font>     and <font color="blue">collaboration <font color="blue">opportunities</font> could</font> be harmed if:           •   We do not achieve our research and <font color="blue">development</font> <font color="blue">objectives</font> under our     <font color="blue">strategic alliance</font> and collaboration <font color="blue"><font color="blue">agreement</font>s</font>;           •   We develop products and processes or <font color="blue">enter into</font> additional strategic     alliances or <font color="blue">collaborations</font> that <font color="blue">conflict with</font> the business <font color="blue">objectives</font> of     our <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font>;           •   We <font color="blue">disagree with</font> our <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font> as to rights     to <font color="blue"><font color="blue">intellectual</font> property</font> we develop, or their <font color="blue">research programs</font> or     <font color="blue">commercialization</font> activities;           •   We are unable to manage multiple simultaneous <font color="blue">strategic alliance</font>s or     <font color="blue">collaborations</font>;           •   Our <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font> become <font color="blue">competitors</font> of ours or     <font color="blue">enter into</font> <font color="blue"><font color="blue">agreement</font>s</font> with our <font color="blue">competitors</font>;           •   Our <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font> become less willing to expend     their <font color="blue">resources on research</font> and <font color="blue">development</font> due to <font color="blue">general market <font color="blue">conditions</font></font>     or other <font color="blue">circumstances beyond</font> our control;           •   <font color="blue">Consolidation </font>in our <font color="blue">target markets</font> limits the number of potential     <font color="blue">strategic partner</font>s or <font color="blue">collaborators</font>; or           •   We are unable to negotiate additional <font color="blue"><font color="blue">agreement</font>s</font> having terms     satisfactory to us</td>
    </tr>
    <tr>
      <td>We may not be able to realize any <font color="blue">future benefits from</font> the products and     programs that we are discontinuing and/or de-emphasizing in <font color="blue">connection with</font>     the <font color="blue">strategic reorganization</font> that we announced in January 2006</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2006, we announced a <font color="blue">strategic reorganization</font> designed to focus     our <font color="blue">resources on programs</font> and products that have the <font color="blue">greatest opportunity</font>     for success</td>
    </tr>
    <tr>
      <td>Accordingly, we elected to <font color="blue">discontinue</font> or to <font color="blue">exit certain</font>     products and programs, many of which we have spent <font color="blue">significant</font> amounts of     <font color="blue">research funds on</font> to date</td>
    </tr>
    <tr>
      <td>We <font color="blue">will attempt</font> to sell and/or out-license to     third  parties some of these products and programs, including, but not     limited to, our sordarins anti-fungal program, our <font color="blue">recombinant natural</font>     <font color="blue">products program</font>, and our <font color="blue">animal health programs</font></td>
    </tr>
    <tr>
      <td>It is possible that we     could be <font color="blue">unsuccessful</font> in our attempts to sell or out-license these products     and/or                                           26     ______________________________________________________________________       programs</td>
    </tr>
    <tr>
      <td>In the event that we are successful in selling or out-licensing     any of these products and/or programs, the structure of <font color="blue">such transactions</font>     may provide for <font color="blue">only future compensation</font> in the event that the <font color="blue">third party</font>     is <font color="blue">ultimately successful</font> in <font color="blue">development</font> of the products and/or programs</td>
    </tr>
    <tr>
      <td>Accordingly, it is possible that we may not receive any <font color="blue">financial benefit</font>     from any sale or out license of these products and/or programs</td>
    </tr>
    <tr>
      <td>We do not own <font color="blue">equipment with</font> the <font color="blue">capacity</font> to <font color="blue"><font color="blue">manufacture</font> <font color="blue">products on</font></font> a     <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>If we are unable to access the <font color="blue">capacity</font> to <font color="blue">manufacture</font>     products in <font color="blue">sufficient quantity</font>, we may not be able to <font color="blue">commercialize</font> our     products or generate <font color="blue">significant</font> sales</td>
    </tr>
    <tr>
      <td>We have only limited experience in <font color="blue">enzyme <font color="blue">manufacturing</font></font>, and we do not have     our own <font color="blue">capacity</font> to <font color="blue"><font color="blue">manufacture</font> <font color="blue">products on</font></font> a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>We expect to     be <font color="blue">dependent</font> to a <font color="blue">significant</font> extent on <font color="blue">third parties</font> for <font color="blue">commercial scale</font>     <font color="blue">manufacturing</font> of our products</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">arrangements</font> with <font color="blue">third parties</font></font> that     have  the  required  <font color="blue">manufacturing</font> equipment and available <font color="blue">capacity</font> to     <font color="blue">manufacture</font> Ultra-Thin^™ enzyme, Phyzyme^™ XP, Bayovac^® SRS, Quantum^™     phytase, Luminase^™ PB-100 enzyme, Pyrolase 160 enzyme, Pyrolase 200 enzyme,     and Cottonase^™ enzyme</td>
    </tr>
    <tr>
      <td>While we have our own pilot <font color="blue">development</font> facility, we     continue  to  depend  on  third  parties  for  large-scale  commercial     <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Additionally, one of our <font color="blue">third party</font> <font color="blue">manufacture</font>rs is located     in a <font color="blue">foreign country</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">difficult</font>ies</font> or <font color="blue">interruptions</font> of <font color="blue">service with</font> our     <font color="blue">third party</font> <font color="blue">manufacture</font>rs or our own pilot <font color="blue">manufacturing</font> facility could     disrupt our research and <font color="blue">development</font> efforts, delay our <font color="blue">commercialization</font> of     products,  and  harm  our  <font color="blue">relationships</font>  with our <font color="blue">strategic partner</font>s,     <font color="blue">collaborators</font>, or customers</td>
    </tr>
    <tr>
      <td>We have only limited experience in in<font color="blue">dependent</font>ly developing, <font color="blue">manufacturing</font>,     marketing, selling, and <font color="blue">distributing commercial products</font></td>
    </tr>
    <tr>
      <td>We intend to pursue some product <font color="blue">opportunities</font> in<font color="blue">dependent</font>ly</td>
    </tr>
    <tr>
      <td>We currently     have only limited resources and <font color="blue">capability</font> to develop, <font color="blue">manufacture</font>, market,     sell, or <font color="blue"><font color="blue">distribute products</font> on</font> a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>We will determine which     products to pursue in<font color="blue">dependent</font>ly based on various criteria, including:     <font color="blue">investment</font>  required,  estimated  time  to market, <font color="blue">regulatory</font> hurdles,     <font color="blue">infrastructure <font color="blue">requirements</font></font>, and industry-specific expertise <font color="blue">necessary</font> for     successful <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>At any time, we may modify our strategy and     pursue <font color="blue">collaborations</font> for the <font color="blue">development</font> and <font color="blue">commercialization</font> of some     products  that  we had intended to pursue in<font color="blue">dependent</font>ly</td>
    </tr>
    <tr>
      <td>We may pursue     products that ultimately require more <font color="blue">resources than</font> we anticipate or which     may be technically <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>In order for us to <font color="blue">commercialize</font> more     <font color="blue">products directly</font>, we would need to establish or obtain <font color="blue">through outsourcing</font>     <font color="blue">arrangements</font> additional <font color="blue">capability</font> to develop, <font color="blue">manufacture</font>, market, sell,     and <font color="blue">distribute products</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> <font color="blue">commercialize</font>     products resulting from our internal product <font color="blue">development</font> efforts, we will     continue to <font color="blue">incur losses</font></td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">successfully</font> develop a commercial     product, we may not generate <font color="blue">significant</font> sales and achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Ethical, legal, and social concerns about <font color="blue">genetically</font> engineered products     <font color="blue">could limit</font> or prevent the use of our products and <font color="blue">technologies</font> and limit     our revenue</td>
    </tr>
    <tr>
      <td>Some of our anticipated products are <font color="blue">genetically</font> engineered</td>
    </tr>
    <tr>
      <td>If we and/or     our <font color="blue">collaborators</font> are not able to overcome the ethical, legal, and social     concerns relating to <font color="blue">genetic engineering</font>, our <font color="blue">products may</font> not be accepted</td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">risks discussed</font> below could result in expenses, delays, or other     <font color="blue">impediments</font> to our programs or the <font color="blue">public <font color="blue">acceptance</font></font> and <font color="blue">commercialization</font>     of products <font color="blue">dependent</font> on our <font color="blue">technologies</font> or <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our ability to     develop and <font color="blue">commercialize</font> one or more of our <font color="blue">technologies</font> and products could     be limited by the <font color="blue">following factors</font>:           •   Public attitudes about the safety and <font color="blue">environmental hazards</font> of, and     ethical concerns over, <font color="blue">genetic research</font> and <font color="blue">genetically</font> engineered products,     <font color="blue">which could</font> influence <font color="blue">public <font color="blue">acceptance</font></font> of our <font color="blue">technologies</font> and products;           •   Public attitudes regarding, and potential changes to <font color="blue">laws governing</font>,     ownership of genetic material <font color="blue">which <font color="blue">could harm</font></font> our <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">rights with respect</font> to our genetic material and <font color="blue">discourage <font color="blue">collaborative</font></font>     <font color="blue">partners from supporting</font>, developing, or <font color="blue">commercializing</font> our products and     <font color="blue">technologies</font>; and                                           27     ______________________________________________________________________         •   <font color="blue">Governmental </font>reaction to negative publicity concerning <font color="blue">genetically</font>     modified organisms, <font color="blue">which could</font> result in <font color="blue">greater <font color="blue">government</font> regulation</font> of     <font color="blue">genetic research</font> and <font color="blue">derivative products</font>, including <font color="blue">labeling <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>The  subject  of  <font color="blue">genetically</font> modified organisms has received negative     publicity, which has <font color="blue">aroused public debate</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">adverse publicity could lead</font>     to <font color="blue">greater regulation</font> and <font color="blue">trade restrictions on imports</font> of <font color="blue">genetically</font>     <font color="blue">altered products</font></td>
    </tr>
    <tr>
      <td>If  we are unable to continue to <font color="blue">collect genetic</font> material <font color="blue">from diverse</font>     <font color="blue">natural <font color="blue">environments</font></font>, our research and <font color="blue">development</font> efforts and our product     <font color="blue">development</font> programs could be harmed</td>
    </tr>
    <tr>
      <td>We <font color="blue">collect genetic</font> material <font color="blue">from organisms found</font> in <font color="blue">diverse <font color="blue">environments</font></font></td>
    </tr>
    <tr>
      <td>We     collect material from <font color="blue">government</font>-owned land in <font color="blue">foreign countries</font> and in     areas of the <font color="blue"><font color="blue">United States</font> </font>under formal resource access <font color="blue"><font color="blue">agreement</font>s</font> and from     <font color="blue">private lands under</font> individual <font color="blue"><font color="blue">agreement</font>s</font> with private landowners</td>
    </tr>
    <tr>
      <td>If our     access  to  materials  under  <font color="blue">biodiversity</font>  access <font color="blue"><font color="blue">agreement</font>s</font> or other     <font color="blue">arrangements</font> is reduced or terminates, it <font color="blue">could harm</font> our internal and our     <font color="blue"><font color="blue">collaborative</font> research</font> and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We <font color="blue">also collect samples from</font>     other <font color="blue">environments</font> where <font color="blue"><font color="blue">agreement</font>s</font> are currently not required, such as the     deep sea</td>
    </tr>
    <tr>
      <td>All of our <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">foreign countries</font> expire in 2008 or     earlier, are renewable, and are all subject to earlier <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">voluntarily ceased collections</font> of <font color="blue">further samples</font> in Yellowstone National     Park pending the park’s resolution of <font color="blue">collection guidelines</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">compete may decline</font> if we do not <font color="blue"><font color="blue">adequately</font> protect</font> our     <font color="blue">proprietary</font> <font color="blue">technologies</font> or if we lose some of our <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">rights due</font> to <font color="blue">becoming involved</font> in <font color="blue">expensive lawsuits</font> or <font color="blue">administrative</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to obtain patents and maintain     <font color="blue">adequate protection</font> of our other <font color="blue"><font color="blue">intellectual</font> property</font> for our <font color="blue">technologies</font>     and products in the <font color="blue"><font color="blue">United States</font> </font>and other countries</td>
    </tr>
    <tr>
      <td>The laws of some     <font color="blue">foreign countries</font> do not <font color="blue">protect <font color="blue">proprietary</font> rights</font> to the <font color="blue">same extent as</font>     the  laws  of  the  <font color="blue">United States</font>, and many companies have <font color="blue">encountered</font>     <font color="blue">significant</font> problems in protecting their <font color="blue">proprietary</font> rights in these foreign     countries</td>
    </tr>
    <tr>
      <td>These problems can be caused by, for example, a lack of rules and     methods for defending <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>Our  commercial  <font color="blue">success depends</font> in part on not <font color="blue">infringing patents</font> and     <font color="blue">proprietary</font> rights of <font color="blue">third parties</font>, and not breaching any licenses or other     <font color="blue"><font color="blue">agreement</font>s</font>  that we have <font color="blue">entered into with</font> regard to our <font color="blue">technologies</font>,     products, and business</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">patent position</font>s</font> of <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font>,     including our <font color="blue">patent position</font>, involve complex legal and factual questions     and, therefore, enforceability cannot be <font color="blue">predicted with certainty</font></td>
    </tr>
    <tr>
      <td>We will     apply for <font color="blue">patents covering both</font> our <font color="blue">technologies</font> and <font color="blue">products as</font> we deem     <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>Patents,  if  issued, may be challenged, invalidated, or     <font color="blue"><font color="blue">circumvent</font>ed</font></td>
    </tr>
    <tr>
      <td>We cannot be sure that <font color="blue">relevant patents</font> have not <font color="blue">been issued</font>     that <font color="blue">could block</font> our ability to obtain patents or to operate as we would     like</td>
    </tr>
    <tr>
      <td>Others may develop similar <font color="blue">technologies</font> or duplicate <font color="blue">technologies</font>     developed by us</td>
    </tr>
    <tr>
      <td>There may be patents in some countries that, if valid, may     block our ability to <font color="blue">commercialize</font> products in these countries if we are     <font color="blue">unsuccessful</font> in <font color="blue"><font color="blue">circumvent</font>ing</font> or acquiring the rights to these patents</td>
    </tr>
    <tr>
      <td>There also may be claims in <font color="blue">published patent <font color="blue"><font color="blue">application</font>s</font></font> in some countries     that, if granted and valid, may also block our ability to <font color="blue">commercialize</font>     products in these countries if we are unable to <font color="blue">circumvent</font> or <font color="blue">license them</font></td>
    </tr>
    <tr>
      <td>In 2003, an <font color="blue"><font color="blue">interference</font> proceeding</font> was declared in the US Patent and     <font color="blue">Trademark Office </font>in 2004 between a US patent assigned to us and a pending     US patent owned by another <font color="blue">company with allowable</font> claims directed to     <font color="blue">optimization</font>  of  <font color="blue">immunomodulatory</font>  genetic  vaccines</td>
    </tr>
    <tr>
      <td>Other than this     <font color="blue"><font color="blue">interference</font> proceeding</font>, we are not currently a party to any <font color="blue"><font color="blue">litigation</font> with</font>     regard  to our <font color="blue">patent position</font></td>
    </tr>
    <tr>
      <td>However, the <font color="blue">bio<font color="blue">technology</font></font> industry is     <font color="blue">characterized</font>  by  extensive  <font color="blue">litigation</font>  regarding  patents and other     <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>Many <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font> have employed     <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> as a way to gain a <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">became involved</font> in <font color="blue">litigation</font> or <font color="blue">interference</font> <font color="blue">proceedings</font> declared by     the <font color="blue"><font color="blue">United States</font> </font>Patent and Trademark Office, or                                           28     ______________________________________________________________________       <font color="blue">oppositions</font> or other <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">proceedings</font> outside of the United     States, to defend our <font color="blue"><font color="blue">intellectual</font> property</font> rights or as a result of alleged     <font color="blue">infringement</font> of the rights of others, we might have to spend <font color="blue">significant</font>     amounts of money</td>
    </tr>
    <tr>
      <td>We are aware of a <font color="blue">significant</font> number of patents and patent     <font color="blue"><font color="blue">application</font>s</font> relating to aspects of our <font color="blue">technologies</font> filed by, and issued     to,  third  parties</td>
    </tr>
    <tr>
      <td>Should  any of our <font color="blue">competitors</font> have <font color="blue">filed patent</font>     <font color="blue"><font color="blue">application</font>s</font> or obtained patents that claim <font color="blue">inventions</font> also claimed by us,     we may have to <font color="blue">participate</font> in an <font color="blue"><font color="blue">interference</font> proceeding</font> declared by the     <font color="blue">relevant patent <font color="blue">regulatory</font> agency</font> to determine priority of invention and,     thus, the right to a patent for these <font color="blue">inventions</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>a proceeding, like the one described above, could result in substantial cost     to us even if the outcome is favorable</td>
    </tr>
    <tr>
      <td>Even if <font color="blue">successful on priority</font>     grounds, an <font color="blue">interference</font> may result in loss of claims <font color="blue">based on patentability</font>     <font color="blue">grounds raised</font> in the <font color="blue">interference</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">litigation</font> or <font color="blue">proceedings</font> could     divert our <font color="blue">management</font>’s time and efforts</td>
    </tr>
    <tr>
      <td>Even <font color="blue">unsuccessful</font> claims could     result in <font color="blue">significant</font> legal fees and other expenses, diversion of <font color="blue">management</font>     time,  and  <font color="blue">disruption</font>  in  our business</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from     <font color="blue">initiation</font> and <font color="blue">continuation</font> of any patent or related <font color="blue">litigation</font> <font color="blue">could harm</font>     our ability to compete</td>
    </tr>
    <tr>
      <td>An  adverse  ruling  arising out of any <font color="blue"><font color="blue">intellectual</font> property</font> dispute,     including an <font color="blue">adverse decision as</font> to the priority of our <font color="blue">inventions</font>, would     undercut or invalidate our <font color="blue"><font color="blue">intellectual</font> property</font> position</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse ruling</font>     <font color="blue">could also</font> subject us to <font color="blue">significant</font> <font color="blue">liability</font> for damages, prevent us from     <font color="blue">using processes</font> or products, or require us to <font color="blue">negotiate licenses</font> to disputed     rights  from  <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Although patent and <font color="blue"><font color="blue">intellectual</font> property</font>     disputes in the <font color="blue">bio<font color="blue">technology</font></font> area are <font color="blue">often settled through licensing</font> or     similar  <font color="blue">arrangements</font>, costs associated with these <font color="blue">arrangements</font> may be     substantial and could include <font color="blue">ongoing royalties</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">necessary</font>     <font color="blue">licenses may</font> not be available to us on satisfactory terms, if at all</td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue"><font color="blue">difficult</font>ies</font> managing our growth, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our strategy includes <font color="blue">entering into</font> and working <font color="blue">on simultaneous</font> projects     <font color="blue">across multiple <font color="blue">industries</font></font></td>
    </tr>
    <tr>
      <td>While we do not expect to <font color="blue">significant</font>ly increase     our <font color="blue">headcount</font> in the near future, if we add more projects, it may place     <font color="blue">increased demands on</font> our limited <font color="blue">human resources</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">effectively</font>     manage our <font color="blue">operations</font>, growth, and various projects requires us to continue     to improve our operational, financial and <font color="blue">management</font> controls, reporting     systems and procedures and to attract and retain <font color="blue">sufficient numbers</font> of     talented  employees</td>
    </tr>
    <tr>
      <td>We  may  not  be  able to <font color="blue">successfully</font> implement     <font color="blue">improvements</font>  to  our <font color="blue">management</font> information and <font color="blue">control systems</font> in an     <font color="blue">efficient</font> or <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may discover deficiencies</font> in     <font color="blue">existing systems</font> and controls</td>
    </tr>
    <tr>
      <td><font color="blue">Confidentiality </font><font color="blue"><font color="blue">agreement</font>s</font> with employees and others may not <font color="blue">adequately</font>     <font color="blue">prevent disclosure</font> of <font color="blue">trade secrets</font> and other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>In order to protect our <font color="blue">proprietary</font> <font color="blue">technology</font> and processes, we also rely     in part <font color="blue">on trade secret protection</font> for our <font color="blue">confidential</font> and <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>We have <font color="blue">taken security measures</font> to protect our <font color="blue">trade secrets</font>     and  <font color="blue">proprietary</font>  information</td>
    </tr>
    <tr>
      <td>These <font color="blue">measures may</font> not <font color="blue">provide adequate</font>     protection for our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Our     policy is to execute <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> with our employees and     <font color="blue">consultants upon</font> the <font color="blue">commencement</font> of an <font color="blue">employment</font> or <font color="blue">consulting arrangement</font>     with  us</td>
    </tr>
    <tr>
      <td>These  <font color="blue"><font color="blue">agreement</font>s</font>  <font color="blue">generally</font>  require that all <font color="blue">confidential</font>     information developed by the individual or made known to the individual by     us  during the course of the individual’s <font color="blue">relationship with</font> us be kept     <font color="blue">confidential</font> and not disclosed to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> also     <font color="blue">generally</font> provide that <font color="blue">inventions</font> conceived by the individual in the course     of rendering services to us shall be our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that <font color="blue">proprietary</font> information will not be disclosed, that others     will  not  in<font color="blue">dependent</font>ly  develop <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font>     information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font>, or     that  we  can  <font color="blue">meaningfully</font>  protect  our  trade  secrets</td>
    </tr>
    <tr>
      <td>Costly and     time-consuming <font color="blue">litigation</font> could be <font color="blue">necessary</font> to enforce and determine the     scope of our <font color="blue">proprietary</font> rights, and failure to obtain or maintain trade     secret protection could <font color="blue">adversely</font> affect our <font color="blue">competitive</font> business position</td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________       Many potential <font color="blue">competitors</font> who have <font color="blue">greater resources</font> and experience than we     do may develop products and <font color="blue">technologies</font> that make <font color="blue">ours obsolete</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> industry is <font color="blue">characterized</font> by rapid <font color="blue">technological</font> change,     and the area of biomolecule <font color="blue">discovery</font> and <font color="blue">optimization</font> from <font color="blue">biodiversity</font> is     a <font color="blue">rapidly evolving field</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend on</font> our ability to     maintain a <font color="blue">competitive</font> position with respect to <font color="blue"><font color="blue">technological</font> advances</font></td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font> <font color="blue">development</font> by others may result in our products and     <font color="blue">technologies</font> becoming obsolete</td>
    </tr>
    <tr>
      <td>We face, and <font color="blue">will continue</font> to face, intense <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>We are not aware of     another company that has the scope and <font color="blue">integration</font> of <font color="blue">technologies</font> and     processes  that we have</td>
    </tr>
    <tr>
      <td>There are, however, a number of companies who     <font color="blue">compete with us</font> in various steps <font color="blue">throughout</font> our <font color="blue"><font color="blue">technology</font> process</font></td>
    </tr>
    <tr>
      <td>For     example,  Codexis,  Maxygen, Inc, Evotec, and Xencor have <font color="blue">alternative</font>     evolution <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Integrated Genomics Inc, Myriad Genetics, Inc, and     ArQule, Inc</td>
    </tr>
    <tr>
      <td>perform screening, sequencing, and/or bioinformatics services</td>
    </tr>
    <tr>
      <td>Novozymes A/S and Genencor International Inc</td>
    </tr>
    <tr>
      <td>are involved in <font color="blue">development</font>,     overexpression, fermentation, and <font color="blue">purification</font> of enzymes</td>
    </tr>
    <tr>
      <td>Abgenix, Inc,     Cambridge Antibody Technology, Medarex, Inc, and Morphosys AG are involved     in the <font color="blue">development</font> of <font color="blue">human monoclonal antibodies</font></td>
    </tr>
    <tr>
      <td>There are also a number     of  <font color="blue">academic institutions involved</font> in <font color="blue">various phases</font> of our <font color="blue">technology</font>     process</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater financial and     human <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations may</font> develop <font color="blue">technologies</font>     that are superior <font color="blue">alternative</font>s to our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">competitors</font>     may be more <font color="blue">effective at implementing</font> their <font color="blue">technologies</font> for modifying DNA     to develop commercial products</td>
    </tr>
    <tr>
      <td>Any  products that we develop through our <font color="blue">technologies</font> will compete in     multiple, highly <font color="blue">competitive</font> markets</td>
    </tr>
    <tr>
      <td>Many of our potential <font color="blue">competitors</font> in     these markets have <font color="blue">substantially</font> greater financial, technical, and marketing     <font color="blue">resources than</font> we do and may succeed in developing products that would     render  our  products  or  those  of  our  <font color="blue">collaborators</font>  obsolete  or     non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>In addition, many of these <font color="blue">competitors</font> have <font color="blue">significant</font>ly     greater experience than we do in their <font color="blue">respective fields</font></td>
    </tr>
    <tr>
      <td>Our ability to     compete <font color="blue">successfully</font> will depend on our ability to develop <font color="blue">proprietary</font>     products that reach the market in a <font color="blue">timely manner</font> and are <font color="blue"><font color="blue">technological</font>ly</font>     superior to and/or are <font color="blue">less expensive than</font> other <font color="blue">products on</font> the market</td>
    </tr>
    <tr>
      <td>Current <font color="blue">competitors</font> or other <font color="blue">companies may</font> develop <font color="blue">technologies</font> and products     that are more <font color="blue"><font color="blue">effective than</font> ours</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">technologies</font> and <font color="blue">products may</font> be     rendered obsolete or uneconomical by <font color="blue"><font color="blue">technological</font> advances</font> or entirely     <font color="blue">different</font>  approaches developed by one or more of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">existing approaches</font> of our <font color="blue">competitors</font> or <font color="blue">new approaches</font> or <font color="blue">technology</font>     developed by our <font color="blue">competitors</font> may be more <font color="blue">effective than</font> those developed by     us</td>
    </tr>
    <tr>
      <td><font color="blue">Stringent  </font>laws  and  required  <font color="blue">government</font>  approvals  <font color="blue">could delay</font> our     <font color="blue">introduction</font> of products</td>
    </tr>
    <tr>
      <td>All phases, especially the field testing, production, and marketing, of our     <font color="blue">potential products</font> are subject to <font color="blue">significant</font> federal, state, local, and/or     foreign <font color="blue">government</font>al regulation</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">agencies may</font> not allow us to     produce and/or market our products in a <font color="blue">timely manner</font> or <font color="blue">under technically</font>     or  <font color="blue">commercially</font>  <font color="blue">feasible <font color="blue">conditions</font></font>, or at all, <font color="blue">which <font color="blue">could harm</font></font> our     business</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, products for our <font color="blue">target markets</font> are <font color="blue">regulated based on</font>     their <font color="blue">application</font>, by either the Food and Drug Administration, or FDA, the     Environmental Protection Agency, or EPA, or, in the case of plants and     animals, the <font color="blue"><font color="blue">United States</font> </font>Department of Agriculture, or USDA The FDA     regulates drugs, food, and feed, as well as food additives, feed additives,     and substances <font color="blue">generally</font> recognized as safe that are used in the processing     of  food or feed</td>
    </tr>
    <tr>
      <td>While <font color="blue">substantially</font> all of our projects to date have     focused on non-human <font color="blue"><font color="blue">application</font>s</font> of our <font color="blue">technologies</font> and <font color="blue">products outside</font>     of the FDA’s review, in the future we may pursue <font color="blue">collaborations</font> for further     research and <font color="blue">development</font> of <font color="blue">drug products</font> for humans that would require FDA     approval before they could be marketed in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition,     any drug <font color="blue">product candidates</font> must also be <font color="blue">approved by</font> the <font color="blue"><font color="blue">regulatory</font> agencies</font>     of foreign <font color="blue">government</font>s before any product can be sold in those countries</td>
    </tr>
    <tr>
      <td>Under current FDA policy, our products, or products of our <font color="blue">collaborative</font>     <font color="blue">partners incorporating</font> our <font color="blue">technologies</font> or <font color="blue">inventions</font>, to the extent that     they <font color="blue">come within</font> the FDA’s <font color="blue">jurisdiction</font>, may be subject to lengthy FDA     reviews and unfavorable FDA de<font color="blue">termination</font>s if they <font color="blue">raise safety questions</font>     <font color="blue">which cannot</font> be <font color="blue">satisfactorily</font> answered, if                                           30     ______________________________________________________________________       results  from  pre-clinical  or <font color="blue">clinical trials</font> do not <font color="blue">meet <font color="blue">regulatory</font></font>     <font color="blue">requirements</font> or if they are deemed to be <font color="blue">food additives whose safety cannot</font>     be <font color="blue">demonstrate</font>d</td>
    </tr>
    <tr>
      <td>An unfavorable FDA <font color="blue">ruling could</font> be <font color="blue">difficult</font> to resolve and     <font color="blue">could prevent</font> a <font color="blue">product from</font> being <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Even after investing     <font color="blue">significant</font>  time  and  <font color="blue">expenditures</font>, our <font color="blue">collaborators</font> may not obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for any <font color="blue">drug products</font> that <font color="blue">incorporate</font> our <font color="blue">technologies</font>     or <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> have not submitted an investigational new     drug  <font color="blue">application</font>  for  any  product  candidate  that <font color="blue">incorporate</font>s our     <font color="blue">technologies</font> or <font color="blue">inventions</font>, and <font color="blue">no drug product candidate</font> developed with our     <font color="blue">technologies</font> has <font color="blue">been approved</font> for <font color="blue">commercialization</font> in the <font color="blue"><font color="blue">United States</font> </font>or     elsewhere</td>
    </tr>
    <tr>
      <td>The EPA <font color="blue">regulates <font color="blue">biologically derived</font> chemical substances</font> not     within  the  FDA’s <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>An unfavorable EPA ruling <font color="blue">could delay</font>     <font color="blue">commercialization</font>  or  require  <font color="blue">modification</font> of the production process     resulting  in  higher  <font color="blue">manufacturing</font> costs, thereby making the product     uneconomical</td>
    </tr>
    <tr>
      <td>In addition, the USDA may prohibit <font color="blue">genetically</font> engineered     <font color="blue">plants from</font> being grown and <font color="blue">transported except under</font> an exemption, or under     controls so burdensome that <font color="blue">commercialization</font> becomes impracticable</td>
    </tr>
    <tr>
      <td>Our     future <font color="blue">products may</font> not be <font color="blue">exempted by</font> the USDA         The European <font color="blue">regulatory</font> process for these classes of <font color="blue">biologically derived</font>     products has been in a state of flux in the recent past, as the EU attempts     to replace country by country <font color="blue">regulatory</font> procedures with a <font color="blue">consistent</font> EU     <font color="blue">regulatory</font>  standard  in each case</td>
    </tr>
    <tr>
      <td>Other than Japan, most other regions of the world     <font color="blue">generally</font> find adequate either a <font color="blue"><font color="blue">United States</font> </font>or a European clearance     <font color="blue">together with associated data</font> and information for a new <font color="blue">biologically derived</font>     product</td>
    </tr>
    <tr>
      <td>If we require <font color="blue">additional capital</font> to fund our <font color="blue">operations</font>, we may need to     <font color="blue">enter into</font> financing <font color="blue">arrangements</font> with unfavorable terms or <font color="blue">which could</font>     <font color="blue">adversely</font>  affect  the  ownership  interest  and  rights of our common     <font color="blue">stockholders</font> as compared to our other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such financing</font> is not     available, we may need to <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>We  currently anticipate that our available cash resources, short-term     <font color="blue">investment</font>s, receivables, and committed funding from <font color="blue"><font color="blue">collaborative</font> partners</font>     and <font color="blue">government</font> grants will be sufficient to meet our capital <font color="blue">requirements</font>     for the near-term</td>
    </tr>
    <tr>
      <td>However, market <font color="blue">acceptance</font> of our products could be     <font color="blue">slower than</font> anticipated, or we may use a <font color="blue">significant</font> amount of our cash to     <font color="blue">successfully</font> develop and market our products</td>
    </tr>
    <tr>
      <td>Our capital <font color="blue">requirements</font> depend on several factors, including:           •   The level of research and <font color="blue">development</font> <font color="blue">investment</font> required to maintain     our <font color="blue">technology</font> leadership position;           •   Our ability to <font color="blue">enter into</font> new <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue"><font color="blue">collaborative</font> partners</font>     or to extend the terms of our existing <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font>, and the     terms of any <font color="blue">agreement</font> of this type;           •   The <font color="blue">success rate</font> of our <font color="blue">discovery</font> efforts associated with milestones     and royalties;           •   Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> products developed     in<font color="blue">dependent</font>ly and the demand for <font color="blue">such products</font>;           •   The timing and <font color="blue">willingness</font> of <font color="blue">strategic partner</font>s and <font color="blue">collaborators</font> to     <font color="blue">commercialize</font> our products that would result in royalties;           •   Costs of recruiting and retaining qualified personnel; and           •   Our need to acquire or license complementary <font color="blue">technologies</font> or acquire     <font color="blue">complementary businesses</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">additional capital</font> is required to operate our business, we <font color="blue">cannot assure</font>     you that <font color="blue">additional financing will</font> be <font color="blue"><font color="blue">available on</font> terms</font> favorable to us, or     at  all</td>
    </tr>
    <tr>
      <td>If  <font color="blue">adequate funds</font> are not available or are not <font color="blue">available on</font>     acceptable terms, our ability to fund our <font color="blue">operations</font>, take advantage of     <font color="blue">opportunities</font>, develop products or <font color="blue">technologies</font>, or otherwise respond to     <font color="blue">competitive</font>  <font color="blue">pressures could</font> be <font color="blue">significant</font>ly limited</td>
    </tr>
    <tr>
      <td>In addition, if     financing is not available, we may need to <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________       If we <font color="blue">raise additional funds through</font> the issuance of <font color="blue">equity securities</font>, the     <font color="blue">percentage ownership</font> of our <font color="blue">stockholders</font> will be reduced, <font color="blue">stockholders</font> may     experience <font color="blue">additional dilution</font> or such <font color="blue">equity securities</font> may provide for     rights, preferences or <font color="blue">privileges senior</font> to those of the holders of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise additional funds through</font> the issuance of debt     securities,  such  debt  <font color="blue">securities would</font> have rights, preferences and     <font color="blue">privileges senior</font> to holders of <font color="blue">common stock</font> and the terms of such debt     <font color="blue">could impose restrictions on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect that our quarterly results of <font color="blue">operations</font> will fluctuate, and this     <font color="blue">fluctuation could</font> cause our stock price to decline, causing <font color="blue">investor losses</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">fluctuations</font> could</font> cause our stock price to     fluctuate <font color="blue">significant</font>ly or decline</td>
    </tr>
    <tr>
      <td>Revenue in future periods may be greater     or  less  than  revenue  in the <font color="blue">immediately preceding period</font> or in the     <font color="blue">comparable period</font> of the prior year</td>
    </tr>
    <tr>
      <td>Some of the factors that could cause     our operating results to fluctuate include:           •   <font color="blue">Termination </font>of <font color="blue">strategic alliance</font>s and <font color="blue">collaborations</font>;           •   The <font color="blue">success rate</font> of our <font color="blue">discovery</font> efforts associated with milestones     and royalties;           •   The ability and <font color="blue">willingness</font> of <font color="blue">strategic partner</font>s and <font color="blue">collaborators</font> to     <font color="blue">commercialize</font>, market, and sell royalty-bearing <font color="blue">products on</font> expected     timelines;           •   Our ability to <font color="blue">enter into</font> new <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">strategic partner</font>s and     <font color="blue">collaborators</font> or to extend the terms of our existing <font color="blue">strategic alliance</font>     <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">collaborations</font>, and the terms of any <font color="blue">agreement</font> of this type;           •   Our ability to <font color="blue">successfully</font> satisfy all pertinent <font color="blue">regulatory</font>     <font color="blue">requirements</font>;           •   Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> products developed     in<font color="blue">dependent</font>ly and the demand for <font color="blue">such products</font>; and           •   General and industry specific economic <font color="blue">conditions</font>, which may affect     our <font color="blue"><font color="blue">collaborative</font> partners</font>’ research and <font color="blue">development</font> <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">revenue declines</font> or does not grow as anticipated due to the expiration of     strategic  alliance or collaboration <font color="blue"><font color="blue">agreement</font>s</font>, failure to obtain new     <font color="blue"><font color="blue">agreement</font>s</font> or grants, lower than expected royalty payments, slow market     <font color="blue">acceptance</font>  of  our  products, or other factors, we may not be able to     <font color="blue">correspondingly</font>  reduce our operating expenses</td>
    </tr>
    <tr>
      <td>A large portion of our     expenses, including expenses for facilities, equipment and personnel, are     <font color="blue">relatively</font> fixed</td>
    </tr>
    <tr>
      <td>Failure to achieve anticipated levels of revenue could     therefore <font color="blue">significant</font>ly harm our operating results for a <font color="blue">particular fiscal</font>     period</td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">possibility</font> of <font color="blue">fluctuations</font> in our revenue and expenses, we     believe that quarter-to-quarter comparisons of our operating results are not     a good <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Our operating results in some     quarters  may  not  meet the <font color="blue">expectations</font> of <font color="blue">stock market analysts</font> and     investors</td>
    </tr>
    <tr>
      <td>In that case, our <font color="blue">stock price would probably decline</font></td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">key personnel</font> or are unable to attract and retain qualified     personnel as <font color="blue">necessary</font>, it <font color="blue">could delay</font> our product <font color="blue">development</font> programs and     harm our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> to a <font color="blue">significant</font> degree upon the <font color="blue">continued contributions</font>     of our executive officers, <font color="blue">management</font>, and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>If we lose the     services of one or more of these people, we may be unable to achieve our     business <font color="blue">objectives</font> or our <font color="blue">stock price could decline</font></td>
    </tr>
    <tr>
      <td>We may not be able to     attract or retain qualified employees in the future due to the intense     <font color="blue">competition</font>  for  qualified  personnel  among  <font color="blue">bio<font color="blue">technology</font></font> and other     <font color="blue">technology</font>-based businesses, particularly in the San Diego area</td>
    </tr>
    <tr>
      <td>If we are     not able to attract and retain the <font color="blue">necessary</font> personnel to accomplish our     business <font color="blue">objectives</font>, we may experience <font color="blue">constraints</font> that will <font color="blue">adversely</font>                                           32     ______________________________________________________________________       affect our ability to meet the demands of our <font color="blue"><font color="blue">collaborative</font> partners</font> in a     <font color="blue">timely fashion</font> or to support our <font color="blue">internal research</font> and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>In particular, our product <font color="blue">development</font> programs depend on our ability to     attract  and  retain  highly  skilled  <font color="blue">scientists</font>, including molecular     biologists, biochemists, and engineers</td>
    </tr>
    <tr>
      <td>Although we believe we will be     successful in attracting and retaining qualified personnel, <font color="blue">competition</font> for     experienced <font color="blue">scientists</font> and other <font color="blue">technical personnel from numerous companies</font>     and academic and other <font color="blue">research institutions may limit</font> our ability to do so     on acceptable terms</td>
    </tr>
    <tr>
      <td>All of our employees are at-will employees, which means     that either the employee or we may terminate their <font color="blue">employment</font> at any time</td>
    </tr>
    <tr>
      <td>Our  planned  <font color="blue">activities will</font> require <font color="blue">additional expertise</font> in specific     <font color="blue">industries</font>  and <font color="blue">areas applicable</font> to the products developed through our     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">activities will</font> require the addition of <font color="blue">new personnel</font>,     including  <font color="blue">management</font>,  and the <font color="blue">development</font> of <font color="blue">additional expertise</font> by     existing <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to acquire these services or to     develop this <font color="blue">expertise could impair</font> the growth, if any, of our business</td>
    </tr>
    <tr>
      <td>If we engage in any <font color="blue"><font color="blue">acquisition</font>s</font>, we will incur a variety of costs and may     <font color="blue">potentially</font>  <font color="blue">face numerous</font> other risks that could <font color="blue">adversely</font> affect our     business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">appropriate</font> <font color="blue">opportunities</font> become available, we may consider acquiring     businesses,  assets,  <font color="blue">technologies</font>,  or products that we believe are a     strategic  fit  with our business</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">no commitments</font> or     <font color="blue"><font color="blue">agreement</font>s</font> with respect to any material <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>If we do <font color="blue">pursue such</font> a     strategy, we could           •   Issue <font color="blue">equity securities</font> which would dilute current <font color="blue">stockholders</font>’     <font color="blue">percentage ownership</font>;           •   Incur substantial debt; or           •   Assume <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>We  may  not be able to <font color="blue">successfully</font> integrate any businesses, assets,     products, <font color="blue">technologies</font>, or personnel that we might acquire in the future     without a <font color="blue">significant</font> expenditure of operating, financial, and <font color="blue">management</font>     resources, if at all</td>
    </tr>
    <tr>
      <td>In addition, future <font color="blue"><font color="blue">acquisition</font>s</font> might negatively     impact our business <font color="blue">relations with</font> our <font color="blue"><font color="blue">collaborative</font> partners</font></td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">recent accounting</font> changes could result in a <font color="blue">negative impact on</font> our results     of <font color="blue">operations</font> as well as the resulting cost of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Any of these     adverse <font color="blue">consequences</font> <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We may be sued for <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>We may be held liable if any product we develop, or any <font color="blue">product which</font> is     made with the use of any of our <font color="blue">technologies</font>, causes injury or is found     otherwise unsuitable during product testing, <font color="blue">manufacturing</font>, marketing, or     sale</td>
    </tr>
    <tr>
      <td>We currently have limited <font color="blue">product <font color="blue">liability</font></font> insurance that may not     <font color="blue">fully cover</font> our potential <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>In addition, if we attempt to obtain     additional <font color="blue">product <font color="blue">liability</font></font> insurance coverage, this <font color="blue">additional insurance</font>     may  be  <font color="blue">prohibitively expensive</font>, or may not <font color="blue">fully cover</font> our potential     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inability  </font>to obtain sufficient insurance coverage at an     acceptable cost or otherwise to protect against potential <font color="blue">product <font color="blue">liability</font></font>     claims <font color="blue">could prevent</font> or inhibit the <font color="blue">commercialization</font> of products developed     by us or our <font color="blue"><font color="blue">collaborative</font> partners</font></td>
    </tr>
    <tr>
      <td>If we are sued for any injury caused by     our products, our <font color="blue">liability</font> could exceed our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>We  are  subject  to  anti-takeover  provisions  in our <font color="blue">certificate</font> of     <font color="blue">incorporation</font>, bylaws, and <font color="blue">Delaware </font>law and have adopted a <font color="blue">shareholder</font>     rights plan that <font color="blue">could delay</font> or prevent an <font color="blue">acquisition</font> of our company, even     if the <font color="blue">acquisition</font> would be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, our bylaws and <font color="blue">Delaware </font>law     could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us, even if doing     so would be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, we adopted a share     <font color="blue">purchase rights</font> plan that has anti-takeover effects</td>
    </tr>
    <tr>
      <td>The <font color="blue">rights under</font> the     plan will cause substantial dilution to a person or group that attempts to     acquire us on terms not <font color="blue">approved by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>The rights     should not <font color="blue">interfere with</font> any merger or other business <font color="blue">combination approved</font>     by our board, since the <font color="blue">rights may</font>                                           33     ______________________________________________________________________       be amended to <font color="blue">permit such</font> an <font color="blue">acquisition</font> or may be <font color="blue">redeemed by us</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions in our charter documents, under <font color="blue">Delaware </font>law, and in our rights     plan <font color="blue">could discourage potential takeover attempts</font> and could <font color="blue">adversely</font> affect     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Because of these provisions, our     common  <font color="blue">stockholders</font>  might  not be able to receive a premium on their     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Our  stock price has been and <font color="blue">may continue</font> to be <font color="blue">particularly volatile</font>     because of the industry we are in</td>
    </tr>
    <tr>
      <td>The stock market, from time to time, has experienced <font color="blue">significant</font> price and     volume <font color="blue">fluctuations</font> that are unrelated to the operating performance of     companies</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s of <font color="blue">technology</font> companies, particularly life     <font color="blue">science companies</font>, have <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td>Our stock has been and may     continue to be <font color="blue">affected by</font> this type of market volatility, as well as by our     own performance</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font>, among other risk factors, may have a     <font color="blue">significant</font> effect on the <font color="blue">market price</font> of our <font color="blue">common stock</font>:           •   <font color="blue">Developments </font>in our <font color="blue">relationships</font> with current or future strategic     partners and <font color="blue">collaborators</font>;           •   <font color="blue">Announcements </font>of <font color="blue">technological</font> <font color="blue">innovations</font> or new products by us or     our <font color="blue">competitors</font>;           •   <font color="blue">Developments </font>in patent or other <font color="blue">proprietary</font> rights;           •   Our ability to <font color="blue">access genetic</font> material <font color="blue">from diverse</font> ecological     <font color="blue">environments</font> and practice our <font color="blue">technologies</font>;           •   Future royalties from <font color="blue">product sales</font>, if any, by our <font color="blue">collaborative</font>     partners;           •   <font color="blue">Fluctuations </font>in our operating results;           •   Litigation;           •   <font color="blue">Developments </font>in domestic and <font color="blue">international</font> <font color="blue">government</font>al policy or     regulation; and           •   Economic and other <font color="blue">external factors</font> or other disaster or crisis</td>
    </tr>
    <tr>
      <td><font color="blue">Concentration  </font>of ownership among our existing officers, <font color="blue">directors</font> and     principal <font color="blue">stockholders</font> may prevent other <font color="blue">stockholders</font> from <font color="blue">influencing</font>     <font color="blue">significant</font> corporate <font color="blue">decisions</font> and depress our stock price</td>
    </tr>
    <tr>
      <td>Our officers, <font color="blue">directors</font>, and <font color="blue">stockholders</font> with at least 5prca of our stock     together controlled <font color="blue">approximately</font> 56dtta9prca of our outstanding <font color="blue">common stock</font> as     of  <font color="blue">February </font>28,  2006</td>
    </tr>
    <tr>
      <td>If  these  officers, <font color="blue">directors</font>, and principal     <font color="blue">stockholders</font> act together, they will be able to exert a <font color="blue">significant</font> degree     of <font color="blue">influence over</font> our <font color="blue">management</font> and affairs and <font color="blue">over matters</font> requiring     <font color="blue">stockholder approval</font>, including the election of <font color="blue">directors</font> and approval of     mergers or other business <font color="blue">combination transactions</font></td>
    </tr>
    <tr>
      <td>In addition, as of     <font color="blue">February </font>28, 2006, Syngenta and its <font color="blue">affiliates</font> controlled <font color="blue">approximately</font> 17prca     of our outstanding <font color="blue">common stock</font>, and by <font color="blue">themselves</font> will be able to exert a     <font color="blue">significant</font> degree of <font color="blue">influence over</font> our <font color="blue">management</font> and affairs and over     matters requiring <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>The interests of this <font color="blue">concentration</font>     of <font color="blue">ownership may</font> not <font color="blue">always coincide with</font> our interests or the interests of     other  <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>For instance, officers, <font color="blue">directors</font>, and principal     <font color="blue">stockholders</font>, acting together, could cause us to <font color="blue">enter into</font> transactions or     <font color="blue"><font color="blue">agreement</font>s</font>  that  we  would  not  otherwise  consider</td>
    </tr>
    <tr>
      <td>Similarly, this     <font color="blue">concentration</font> of <font color="blue">ownership may</font> have the effect of delaying or preventing a     change  in  control  of  our  company  otherwise  <font color="blue">favored by</font> our other     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of <font color="blue">ownership could depress</font> our stock price</td>
    </tr>
    <tr>
      <td>Future sales of our stock by large <font color="blue">stockholders</font> could cause the price of our     stock to decline</td>
    </tr>
    <tr>
      <td>A number of our <font color="blue">stockholders</font> hold <font color="blue">significant</font> amounts of our stock</td>
    </tr>
    <tr>
      <td>For     example, as of <font color="blue">February </font>28, 2006, Syngenta, our <font color="blue">largest stockholder</font>, owned     7cmam963cmam593  shares  of  our  common  stock, or <font color="blue">approximately</font> 17prca of our     <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>All of our shares owned by Syngenta are eligible for     sale  in  the  <font color="blue">public market</font> subject to <font color="blue">compliance with</font> the applicable     <font color="blue">securities laws</font></td>
    </tr>
    <tr>
      <td>We have agreed that, upon Syngenta’s request, we will file     one or more <font color="blue">registration statements under</font> the <font color="blue">Securities Act </font>in order to     permit Syngenta to offer and sell shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Sales of a     substantial  number  of shares of our stock by our large <font color="blue">stockholders</font>,     including Syngenta, in the <font color="blue">public market</font> could <font color="blue">adversely</font> affect the market     price of our stock</td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________       We <font color="blue">use <font color="blue">hazardous</font> materials</font> in our business</td>
    </tr>
    <tr>
      <td>Any claims relating to improper     handling, storage, or disposal of these <font color="blue">materials could</font> be time consuming     and costly</td>
    </tr>
    <tr>
      <td>Our  research  and <font color="blue">development</font> processes involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous</font>  materials,  including chemical, radioactive, and biological     materials</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> also produce <font color="blue">hazardous</font> waste products</td>
    </tr>
    <tr>
      <td>We cannot     <font color="blue">eliminate entirely</font> the risk of <font color="blue">accidental <font color="blue">contamination</font></font> or discharge and any     <font color="blue">resultant injury from</font> these materials</td>
    </tr>
    <tr>
      <td>Federal, state, and <font color="blue">local laws</font> and     <font color="blue">regulations govern</font> the use, <font color="blue">manufacture</font>, storage, handling, and disposal of     these materials</td>
    </tr>
    <tr>
      <td>We may be sued for any injury or <font color="blue">contamination</font> that results     from  our  use or the use by <font color="blue">third parties</font> of these materials, and our     <font color="blue">liability</font>  may  exceed  our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">compliance with</font>     <font color="blue">applicable environmental laws</font> and <font color="blue">regulations may</font> be expensive, and current     or future environmental <font color="blue">regulations may</font> impair our research, <font color="blue">development</font>, or     <font color="blue">production efforts</font></td>
    </tr>
  </tbody>
</table>